Skip to content

A research for folate in preventing carcinogenesis of chronic atrophic gastritis

Clinical trial for folate in preventing carcinogenesis of chronic atrophic gastritis

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020815
Enrollment
Unknown
Registered
2019-01-20
Start date
2019-01-08
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis

Interventions

Group 2:weifuchun folic acid
Group 3:weifuchun folic acid VB12

Sponsors

Jiangsu Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-70 years old, male and female; 2) Gastroscope and pathological diagnosis of chronic atrophic gastritis and / or with mild and moderate dysplasia The standard is based on the New Sydney system, and the two pathologists agree on the pathology before they can be enrolled; 3) Signing informed consent. 4) HP-negative patients were enrolled directly, and positive subjects were enrolled in the HP eradication .

Exclusion criteria

Exclusion criteria: 1. Folic acid, antibiotics (other than HP eradication), antacids and gastric mucosal protective agents; anti-platelet such as aspirin , and anticoagulant drugs such as warfarin in past 1 week; 2. chronic atrophic gastritis with severe hyperplasia, gastric ulcer, duodenal ulcer; gastric cancer; 3. gastric resection; 4. digestive tumors, and other patients with benign or malignant tumors; severe cardiovascular, cerebrovascular, hepatic, renal, hematopoietic Systemic primary diseases and mental illness patients; 5. pregnant lactating women, and allergic constitution; 6. not use the prescribed drugs, not judge the efficacy or data incomplete; 7. In the past month, participated in other clinical drug experiments; 8. alcohol abuse, drug abuse, and mental-related diseases prescribed by law, and could not effectively cooperate with the attending doctor.

Design outcomes

Primary

MeasureTime frame
improvement of endoscopic tissue;

Countries

China

Contacts

Public ContactZhang guoxin

Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University

guoxinz@njmu.edu.cn+86 13951913128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026